Catherine M. Szyman - Aug 2, 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP, Critical Care
Signature: Linda J. Park, Attorney-in-Fact
Stock symbol: EW
Transactions as of: Aug 2, 2021
Transactions value $: -$1,376,504
Form type: 4
Date filed: 8/2/2021, 09:35 PM
Previous filing: Jun 15, 2021
Next filing: Aug 5, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Options Exercise	$326K	+15K	+54.04%	$21.76	42.8K	Aug 2, 2021	Direct
transaction	EW	Common Stock	Sale	-$1.7M	-15K	-35.08%	$113.53	27.8K	Aug 2, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Employee Stock Option (Right to Acquire)	Options Exercise	$0	-15K	-10.14%	$0.00	133K	Aug 2, 2021	Common Stock	15K	$21.76	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed in multiple trades at prices ranging from $113.4450 to $113.7500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.